reactive oxygen species (ROS) generation, which was not affected upon either FLAP or cyclooxygenase-2 inhibition. Prevention of ROS generation by either the free radical scavengers vitamin E and N-(2-mercaptopropionyl)glycine or the NADPH oxidase inhibitor VAS2870 downregulated vasculogenesis of ES cells and blunted the provasculogenic effect of AA. In summary, our data demonstrate that proinflammatory AA stimulates vasculogenesis of ES cells via the LT pathway by mechanisms involving ROS generation.
further processed to form leukotrienes (LTs), the first of which is the unstable LTA 4 . LTA 4 is subsequently converted to LTB 4 by LTA 4 hydrolase or together with glutathione to LTC 4 by LTC 4 synthase and glutathione-Stransferase. LTC 4 is converted by ubiquitous enzymes to form LTD 4 and LTE 4 [Savari et al., 2014] . Interestingly, states of inflammation are also involved in processes of early embryogenesis since embryo implantation is associated with an active T-helper type 1 inflammatory response while a T-helper type 2 humoral inflammation is required for pregnancy maintenance [Dekel et al., 2010; Granot et al., 2012] . These observations suggest that very early events in embryogenesis, e.g. the development of the cardiovascular system, require a proinflammatory state within the embryo. Furthermore, proinflammatory states, e.g. during wound healing, are associated with neoangiogenesis, which may besides sprouting of already existing blood vessels involve vasculogenesis from stem cells residing within the vessel wall or recruited from tissues or the bone marrow.
The aim of the present study was to investigate whether AA would stimulate vasculogenesis from ES cells and to identify reactive oxygen species (ROS) in the LT-mediated signaling pathway involved.
Materials and Methods

Materials
The FLAP inhibitor 3-{3-tert-butylsulfanyl-1-[4-(5-methoxypyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM643) was a generous gift from Panmira Pharmaceuticals (San Diego, Calif., USA). The FLAP inhibitor α-pentyl-3-(2-quinolinylmethoxy)benzenemethanol (REV5901) and LTD 4 were purchased from Biomol (Hamburg, Germany). The LTB 4 receptor (BLT1) inhibitor 6-[6-(3R-hydroxy-1E,5Z-undecadien-1-yl)-2-pyridinyl]-1,5S-hexanediol (U75302), the BLT2 inhibitor 1- [5-ethyl-2-hydroxy-4-{[6-methyl-6-(1H-tetrazol-5-yl) heptyl]oxy}phenyl]-ethanone (LY255283), the cysteinyl LT (CysLT) inhibitor 4-[{(1R, 2E,4E,6Z,9Z)-1-[(1S)-4-carboxy-1-hydroxybutyl]-2,4,6,9-pentadecatetraenyl}thio]-benzoic acid (BAY-u9773), LTB 4 , and 12(S) HETE were obtained from Cayman Chemicals (Ann Arbor, Mich., USA). The free radical scavengers N-(2-mercaptopropionyl)glycine (NMPG) and 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-carboxylic acid (trolox) were obtained from Sigma Aldrich (Deisenhofen, Germany). The NADPH oxidase inhibitor VAS2870 was a generous gift from Vasopharm (Würzburg, Germany).
Methods
Cell Culture of ES Cells and Embryoid Body Formation
Mouse ES cells (line CCE) were grown on mitotically inactivated feeder layers of primary murine embryonic fibroblasts in Iscove's medium (Gibco, Live Technologies, Helgerman Court, Md., USA) supplemented with 15% heat-inactivated FCS (56 ° C, 30 min) (Sigma), 2 m M glutamine (PAA, Cölbe, Germany), 100 μ M 2-mercaptoethanol (Sigma), 1% (v/v) non-essential amino acid stock solution (Biochrom, Berlin, Germany), 1% (v/v) MEM amino acids (Biochrom), 1 m M Na + -pyruvate (Biochrom), 0.4% penicillin/streptomycin (Biochrom), 2.5 μg/ml Plasmocin (InvivoGen, San Diego, Calif., USA) and 1,000 U/ml leukemia-inhibitory factor (Chemicon, Chandler's Ford, UK) in a humidified environment containing 5% CO 2 at 37 ° C and passaged every 2-3 days. Adherent cells (in the following defined as day 0) were enzymatically dissociated using 0.05% trypsin-EDTA in PBS (Gibco) and seeded at a density of 3 × 10 6 cells/ml in 250 ml siliconized spinner flasks (CellSpin; Integra Biosciences, Fernwald, Germany) containing 125 ml Iscove's medium supplemented as described above but devoid of leukemia-inhibitory factor and Plasmocin. After 24 h, 125 ml of medium were added to give a final volume of 250 ml. The spinner flask medium was stirred at 20 rpm using a stirrer system (Integra Biosciences);125 ml cell culture medium was exchanged every day.
Abbreviations used in this paper
Immunohistochemistry
As primary antibodies, rat monoclonal anti-platelet endothelial cell adhesion protein (PECAM)-1 antibody (Merck-Millipore, Billerica, Mass., USA) (dilution 1: 100) and rat monoclonal antivascular endothelial (VE)-cadherin antibody (BD Biosciences, Heidelberg, Germany) were used. Whole-mount embryoid bodies were fixed in ice-cold methanol for 20 min at -20 ° C and washed three times with PBST (PBS containing 0.01% Triton X-100) (Sigma). Blocking against unspecific binding was performed for 60 min with 10% nonfat milk powder dissolved in 0.01% PBST. The cells were subsequently incubated for 120 min at room temperature with primary antibodies dissolved in PBS, supplemented with 10% milk in 0.01% PBST. Thereafter, the cells were washed three times with PBST and reincubated with a Cy5-conjugated goat anti-rat IgG (H+L; Dianova, Hamburg, Germany) at a concentration of 3.8 μg/ml in PBS containing 10% FCS in 0.01% PBST. After washing three times in PBST, cells were stored in PBS until assayed. Fluorescence recordings were performed by means of a confocal laser scanning setup (Leica TCS SP2; Leica, Bensheim, Germany). The confocal setup was equipped with a 5-mW helium/ neon laser, single excitation 633 nm (excitation of Cy5). Emission was recorded at ≥ 665 nm.
Quantification of Vasculogenesis and Fetal Liver Kinase-1+ Endothelial Progenitor Cells in Embryoid Bodies
For the quantification of capillary areas within embryoid bodies, an optical sectioning routine based on confocal laser scanning microscopy was used. Images (512 × 512 pixels) were acquired from PECAM-1-stained embryoid bodies using the extended depth of focus algorithm of the confocal setup. In brief, 5 full frame images, separated by a distance of 20 μm in z-direction, were recorded, which included the information of the capillary area and spatial organization in a 100-μm-thick tissue slice. The acquired images were processed to generate a single in-focus image projection of the vascular structures in the scanned tissue slice. Using the image analysis facilities of the confocal setup, the branching points 
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of vascular structures within the three-dimensional projection were identified and counted in relation to the size of the respective embryoid body.
For visualization of fetal liver kinase (Flk)-1+ cells, a reporter ES cell line was used, which was transfected with a lentiviral vector based on the pGZ-CMV vector (System Biosciences, Palo Alto, Calif., USA) containing enhanced green fluorescent protein (eGFP) under the control of the Flk-1 promotor. The Flk-1-eGFP ES cell line displays a bright green fluorescence in Flk-1+ cells when excited by the 488-nm laser line of the confocal microscope (Em 515-530 nm). As a counter stain (red), the cytopainter deep red fluorescence dye (Ex/Em = 630/650 nm) (Abcam, Cambridge, UK) was used. Flk-1+ cells were counted in a 100-μm-thick optical tissue slice in either untreated 4-day-old embryoid bodies or embryoid bodies treated for 24 h with 100 μ M AA using the Metamorph image analysis software (Visitron Systems, Puchheim, Germany).
Western Blot Analysis Western blot assays were carried out after washing the embryoid bodies in PBS and lysing in lysis buffer [50 m M Tris-HCl (pH 7.5), 150 m M NaCl, 1 m M EDTA, 0.1% SDS, 1% Nonidet P-40], supplemented with protease inhibitor cocktail (Biovision, Hannover, Germany) for 20 min on ice. Samples were centrifuged at 13,000 g for 10 min to pellet the debris. After determination of the protein concentration using a Lowry protein assay, 30 μg of protein samples were boiled, separated in 10% SDS polyacrylamide gels and transferred to PVDF membranes at 20 V for 7 min. Membranes were blocked with 5% (wt/vol) dry fat-free milk powder in TBST (Tris-buffered saline with 0.1% Tween) for 60 min at room temperature. Incubation with primary antibody was performed at 4 ° C overnight. The primary antibodies used were a monoclonal rat anti-mouse PECAM-1 (Merck-Millipore) antibody, a monoclonal rat anti-mouse VE-cadherin (BD Biosciences), a monoclonal rat anti-mouse Flk-1 antibody (New England Biolabs, Frankfurt, Germany), and a polyclonal goat anti-mouse FLAP (Novus Biologicals, Cambridge, UK). After washing with 0.1% TBST, the membrane was incubated with a horseradish peroxidase-conjugated secondary antibody (Cell Signaling Technology) for 60 min at room temperature. The blot was developed using an enhanced chemiluminescence detection kit (Perkin Elmer, Freiburg, Germany) to produce a chemiluminescence signal. ImageJ software [Schindelin et al., 2015] was used to quantify the protein bands from Western blot images. For quantification, the density of protein bands on the Western blot image, which was acquired using the PEQLAB gel documentation system (VWR, Erlangen, Germany), was assessed by ImageJ. The final quantification reflects the relative amounts of protein as a ratio of each protein band to the respective housekeeping protein.
Measurement of ROS Generation
Intracellular ROS levels were measured using the fluorescent dye 2 ′ 7 ′ -dichlorodihydrofluorescein diacetate (H 2 DCF-DA; Life Technologies, Darmstadt, Germany), which is a nonpolar compound that is converted into a nonfluorescent polar derivative (H 2 DCF) by cellular esterases after incorporation into cells. H 2 D-CF is membrane impermeable and is rapidly oxidized to the highly fluorescent 2 ′ ,7 ′ -dichlorofluorescein (DCF) in the presence of intracellular ROS [Sharifpanah et al., 2008] . For the experiments, embryoid bodies were incubated in serum-free medium, and 20 μ M H 2 DCF-DA dissolved in DMSO was added. After 30 min, intracellular DCF fluorescence (corrected for background fluorescence) was evaluated in 3,600-μm 2 regions of interest using an overlay mask unless otherwise indicated. For fluorescence excitation, the 488-nm argon ion laser band of the confocal laser scanning microscope was used. Emission was recorded at an emission band of 515-550 nm.
Statistical Analysis
Data are given as means ± SEM, with n denoting the number of experiments unless otherwise indicated. In immunohistochemical analyses of vascular structures, at least 30 embryoid bodies were analyzed in each experiment. One-way ANOVA for unpaired data and Student's t test were applied as appropriate. A value of p ≤ 0.05 was considered significant.
Results
Stimulation of ES Cell-Derived Vasculogenesis and FLAP Expression by AA
To investigate whether activation of the LT signaling pathway would stimulate vasculogenesis, ES cells were treated with different concentrations (50, 100, and 150 μ M ) of AA from days 3 to 10 of differentiation, and protein expression of PECAM-1 ( fig. 2 a) and VE-cadherin ( fig. 2 c) as well as the differentiation of PECAM-1-positive vascular structures ( fig. 2 b) were assessed. It was apparent that AA stimulated PECAM-1 expression, with maximum effects achieved at concentrations of 50-100 μ M and a decrease at 150 μ M ( fig. 2 a) . Likewise, AA at a concentration of 100 μ M stimulated protein expression of VE-cadherin ( fig. 2 c) . Consequently, the number of PE-CAM-1-positive branching points in embryoid bodies was increased upon treatment with 50 and 100 μ M AA ( fig. 2 b) . Since FLAP is a key enzyme in the metabolism of AA towards LTs, FLAP expression was monitored under conditions of AA treatment. As expected, this treatment resulted in upregulation of FLAP protein expression ( fig. 2 d) .
Vasculogenesis is the de novo blood vessel formation from progenitor cells. To assess whether AA treatment increased the number of Flk-1+ vascular progenitor cells, a reporter gene transgenic Flk-1+ eGFP ES cell line, where eGFP is under control of the Flk-1 promotor, was used ( fig. 3 ) . It was shown that 24-hour treatment of differentiating embryoid bodies on day 3 with 100 μ M AA resulted in augmented numbers of Flk-1+ vascular progenitor cells on day 4 of cell culture ( fig. 3 a,  b ) and increased vascular areas on day 9 ( fig. 3 c) , suggesting that indeed AA stimulated vasculogenesis of ES cells.
Inhibition of AA-Mediated Stimulation of Vasculogenesis by FLAP Inhibitors
FLAP is the rate-limiting enzyme in AA metabolism. We therefore treated embryoid bodies from days 3 to 10 with the FLAP inhibitors AM643 (5 μ M ) and REV5901 (2 μ M ) either in the absence or presence of AA (100 μ M ) and assessed vascular differentiation by immunohistochemistry of PECAM-1-positive vascular structures ( fig. 4 a) . Moreover, we determined protein expression of PECAM-1 and VE-cadherin in Western blot assays under the same experimental conditions ( fig. 4 b) . Our data demonstrated that FLAP inhibitors significantly downregulated the number of branching points as well as protein expression of PECAM-1 and VE-cadherin, indicating inhibition of AA-stimulated vasculogenesis of ES cells upon pharmacological inactivation of FLAP. Notably, functional inhibition of FLAP by AM643 and REV5901 downregulated FLAP protein expression ( fig. 4 c) .
Effects of BLT1, BLT2, and CysLT Receptor Inhibition on Vasculogenesis of ES Cells
LTs act on target cells via specific receptors. CysLTs (e.g. LTE 4 ) are acting via CysLT receptors, which can be inhibited by BAY-u9773. The LTA 4 metabolite LTB 4 is acting on cells via the receptors BLT1 and BLT2, which can be antagonized by the specific BLT1 inhibitor U75302 and the BLT2 inhibitor LY255283. To evaluate the spe- 
Effects of Exogenous Addition of LTs and 12(S)HETE on Vasculogenesis of ES Cells
The data of the present study suggest that AA-mediated vasculogenesis of ES cells could be inhibited upon pharmacological inactivation of FLAP, indicating the involvement of LTs in vasculogenesis of ES cells. To corroborate these data, we incubated embryoid bodies from or 12(S)HETE ( fig. 6 d, e) . In conclusion, these data support the assumption that LTs as well as 12(S)HETE are involved in vasculogenesis of ES cells.
ROS Generation in Embryoid Bodies upon AA Treatment
Previous studies have indicated that AA induces ROS generation in cells [Chien et al., 2013] and cell-free systems [Souabni et al., 2012] via interaction of the p67(phox)-Rac complex with the phagocyte oxidase Nox2 [Matono et al., 2014] . Moreover, our studies have demonstrated that ROS are critically involved in vasculogenesis of ES cells [Sauer et al., 2005; Bekhite et al., 2010] . To investigate whether AA exerted its provasculogenic effects through ROS generation in differentiating ES cells, embryoid bodies (4 days old) were treated with AA (100 μ M ), and ROS generation was evaluated using the ROS-sensitive fluorescence indicator H 2 DCF-DA ( fig. 7 a) . AA treatment for 30 min increased ROS generation and reached maximum levels after 6 h of treatment. Even 20 h after AA treatment, an elevated plateau of ROS generation was observed in ES cells. Application of AA in the presence of either the FLAP inhibitors REV5901 or AM643 or in the presence of nimesulide (100 μ M ), which inhibits COX-2 downstream of AA, failed to inhibit ROS generation, suggesting that ROS are neither generated downstream of FLAP nor downstream of COX-2 ( fig. 7 b) . To link ROS generation by AA to the stimulation of vasculogenesis by this compound, embryoid bodies were treated from days 3 to 10 of differentiation with AA (100 μ M ) either in the presence or absence of the ROS scavengers trolox (100 μ M ) and NMPG (100 μ M ) or the NADPH oxidase inhibitor VAS2870 (50 μ M ) ( fig. 7 c, d ). This treatment totally abolished the stimulation of vasculogenesis by AA as assessed by PECAM-1 immunohistochemistry, and indicated that ROS play a determining role in the vasculogenic stimulation of ES cells. 
Discussion
LTs are decisive players in inflammation and wound healing, which is generally associated with recruitment of blood vessels to the inflamed tissue and may include vascular differentiation of stem cells. Moreover, the early postimplantation embryo is subjected to non-life-threatening inflammatory episodes [Straub et al., 2011] , which may be necessary for the induction of differentiation pathways in stem cells of the inner cell mass. In the present study, it is demonstrated that AA stimulated vasculogenesis of ES cells by increasing the number of vascular branches, protein expression of the endothelial markers VE-cadherin and PECAM-1, as well as by increasing the numbers of Flk-1+ endothelial progenitor cells. Notably, AA significantly increased expression of FLAP, which is an accessory protein for 5-LOX to oxidize AA in two steps to LTA 4 . In human osteosarcoma cells lacking FLAP [Dixon et al., 1990] , or where FLAP is pharmacologically inhibited, transformation of endogenous AA by 5-LOX is efficiently blocked [Peters-Golden and Brock, 2003 ].
Since we assumed that the effect of AA on vasculogenesis of ES cells involved LTs, we coadministered the known FLAP inhibitor REV5901 as well as the newly developed compound AM643 [Stock et al., 2010] , which block the formation of both LTB 4 and the CysLTs (i.e. LTC 4 , LTD 4 , and LTE 4 ). FLAP inhibitors act as broadspectrum LT-modifier drugs and may have a wide range of therapeutic applications in the treatment of asthma, chronic obstructive pulmonary disease, arthritis, cardiovascular disease, and cancer [Sampson, 2009] . Both FLAP inhibitors downregulated endothelial marker expression and abolished the effects of AA on vasculogenesis of ES cells. Notably, FLAP inhibitor treatment resulted in downregulation of FLAP expression which is -to the best of our knowledge -a novel feature of these compounds, and may contribute to the observed inhibition of vasculogenesis. Downregulation of FLAP presumably results in a decrease in provasculogenic LT synthesis with the consequent loss of vasculogenic capacity. Since inhibition of vasculogenesis by FLAP inhibitors strongly suggests the involvement of LTs in signal transduction, we supplemented the cell culture medium with exogenous LTB 4 , LTD 4 as well as 12(S)HETE in the absence and presence of FLAP inhibitors. As assumed, treatment with LTB 4 and LTD 4 restored vasculogenesis towards the control level, despite the presence of FLAP inhibitors. The reversing effect of 12(S)HETE on vasculogenesis was somehow unexpected, since this compound is synthesized from AA via the 12-LOX pathway. However, previous studies have shown that the highly selective FLAP inhibitor 655,238 inhibited 12(S)HETE production in human platelets, but had no effect on 12-LOX activity [Ozeki et al., 1999] , which points towards a potential interaction between the 5-LOX and the 12-LOX pathway.
LTs act on target cells via G-protein-coupled LT receptors. In differentiating ES cells, the expression of BLT1, BLT2 as well as CysLT1 receptor and CysLT2 receptor has been shown previously . To investigate the involvement of specific receptors on vasculogenesis of ES cells, we used the specific BLT1 antagonist U75302, the specific BLT2 inhibitor LY255283 as well as the CysLT receptor inhibitor BAY-u9773. Each of these inhibitors partially downregulated the expression of vascular markers, indicating that not only one single LT receptor subtype was responsible for AA-mediated vasculogenesis, but presumably all receptor subtypes were involved. Previously, it has been evidenced that the CysLT1 receptor blocker montelukast, but not the CysLT2 receptor blocker BAYcyslt2, inhibited microvessel outgrowth from rat thoracic aortic rings [Xu et al., 2010] . The same group reported that LTD4 stimulated migration but not proliferation of human endothelial cells upon CysLT1 receptor activation [Yuan et al., 2009] . Moreover, BLT2 has been shown to be involved in proangiogenic processes since BLT2 inhibition by LY255283 almost completely blocked VE growth factor (VEGF)-induced vessel formation from human endothelial cells in Matrigel plug assays, and VEGF significantly upregulated BLT2 expression in human umbilical vein endothelial cells [Kim et al., 2009] . BLT2 as well as BLT1 are expressed on human endothelial cells [Kim et al., 2009; Johansson et al., 2010] . In human immature endothelial progenitor cells isolated from the bone marrow, LTB 4 stimulated cell migration, presumably via direct interaction with BLT1 receptors, which are prominently expressed on this cell type [Walenta et al., 2011] . VEGF and VEGF receptors are induced by hypoxia in tumor tissue. Moreover, an altered metabolism of AA by COX and LOX is a common feature of several epithelial-derived malignancies and has been shown to have crucial roles in cancer progression [Wang and DuBois, 2010] . This suggests a close interaction between AA-and VEGF-mediated signaling pathways.
Tissue inflammation is generally associated with the generation of ROS, which do not only play deleterious effects in cells by exerting oxidative stress, but also regulate the expression of a plethora of signaling pathways, regulating the expression of pro-and anti-inflammatory cytokines and growth factors like VEGF, fibroblast growth factor-2 and platelet-derived growth factor-BB [Sauer et 
